Floatz logo

Trastuzumab Deruxtecan

Colon Cancer Metastatic

M.D. Anderson Cancer Centerantibody_drug_conjugatePhase 2Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

839 Active assets in the Colon Cancer Metastatic cohort.

Asset / SponsorPhaseRating
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
MARBLE DUST
James Varani
Phase 2/3BB
PANITUMUMAB
M.D. Anderson Cancer Center
Phase 3BB
Cetuximab
Shanghai Henlius Biotech
Phase 4BB
FLUOROURACILUM
Washington University School of Medicine
Phase 4BB

View all 50 →

Same molecule, other indications

Trastuzumab Deruxtecan is also rated in:

HER2-low Expressing Breast CancerDormant
BBB
Indicative ·
77 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →
metastatic malignant neoplasm in the brainDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →